48,860
edits
Difference between revisions of "Prostate cancer"
Jump to navigation
Jump to search
→Prostate carcinoma versus urothelial carcinoma
| Line 550: | Line 550: | ||
*GATA3 -ve (+ve in UCC). | *GATA3 -ve (+ve in UCC). | ||
Another panel: | Another panel - if GATA3 isn't available: | ||
*Prostate: PSA +ve, | *Prostate: PSA +ve, p63 -ve, HWMCK -ve. | ||
*Urothelial: | *Urothelial: p63 +ve, HWMCK +ve, PSA -ve. | ||
Note: | Note: | ||
*AMACR not useful - positive in ~ 50% of [[UCC]].<ref name=pmid16315020>{{Cite journal | last1 = Langner | first1 = C. | last2 = Rupar | first2 = G. | last3 = Leibl | first3 = S. | last4 = Hutterer | first4 = G. | last5 = Chromecki | first5 = T. | last6 = Hoefler | first6 = G. | last7 = Rehak | first7 = P. | last8 = Zigeuner | first8 = R. | title = Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. | journal = Virchows Arch | volume = 448 | issue = 3 | pages = 325-30 | month = Mar | year = 2006 | doi = 10.1007/s00428-005-0129-6 | PMID = 16315020 }}</ref> | *AMACR not useful - positive in ~ 50% of [[UCC]].<ref name=pmid16315020>{{Cite journal | last1 = Langner | first1 = C. | last2 = Rupar | first2 = G. | last3 = Leibl | first3 = S. | last4 = Hutterer | first4 = G. | last5 = Chromecki | first5 = T. | last6 = Hoefler | first6 = G. | last7 = Rehak | first7 = P. | last8 = Zigeuner | first8 = R. | title = Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. | journal = Virchows Arch | volume = 448 | issue = 3 | pages = 325-30 | month = Mar | year = 2006 | doi = 10.1007/s00428-005-0129-6 | PMID = 16315020 }}</ref> | ||
*CK7 and CK20 classically are -ve in prostate carcinoma, and positive in urothelial carcinoma. | |||
===Rate of utilization=== | ===Rate of utilization=== | ||